Karuna Therapeutics(KRTX) - 2023 Q4 - Annual Results

Exhibit 99.1 Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults under review with a Prescription Drug User Fee Act (PDUFA) action date of September 26, 2024 Results from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia published in The Lancet Announced appointments of Andrew Miller, Ph.D. as President of Research and Development and Mia Kelley, J.D. as Gen ...